Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085543 | 0.93 | CYP3A4 (0.87) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1085097 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12605237 | 0.90 | CYP2C19 (0.83) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1093342 | 0.90 | CYP2C9 (0.88) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1086108 | 0.88 | CYP2C19 (0.81) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1085824 | 0.88 | CYP2C19 (1.00) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1085748 | 0.87 | CYP3A4 (0.81) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL13627050 | 0.85 | CYP3A4 (0.82) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1085722 | 0.84 | CYP3A4 (0.75) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1820202 | 0.83 | CYP3A4 (0.86) | CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | CYP3A4 3358/4885CYP2C19 2661/4885CYP2C9 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.